Adeel Razi
Professor of Computational Neuroscience at Monash University
Data updated
Research Footprint
Adeel Razi appears in 10 tracked papers (2019–2026), most studied alongside Psilocybin, LSD and MDMA, across Neuroimaging & Brain Measures, Healthy Volunteers and Depressive Disorders.
Most-cited paper: Effective connectivity changes in LSD-induced altered states of consciousness in humans (301 citations).
Frequent co-authors: Devon Stoliker, Katrin Preller and Gary Egan.
Background & Research
Adeel Razi is Professor of Computational Neuroscience at the Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, where he directs the Computational Neuroscience Laboratory. His work combines mathematical modeling, neuroimaging, and machine learning to study brain computation, consciousness, and psychiatric disorders, including psychedelic drug effects.
Key Impact
He is a leading computational neuroscientist applying effective connectivity and Bayesian/active-inference models to understand how psychedelics such as LSD and psilocybin alter consciousness, ego dissolution, and large-scale brain networks.
Collaboration Network
22 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Adeel Razi is associated with.
Monash University
academicThe Clinical Psychedelic Lab, led by Dr. Paul Liknaitzky, conducts robust clinical trials exploring the efficacy and safety of psychedelic-assisted therapies for various mental health conditions within the Australian healthcare context.
View stakeholder →University College London
academicThe Understanding Neuroplasticity Induced by Tryptamines (UNITY) Project was launched at University College London. UNITY represents the first-in-human study of psychedelics at UCL. The team utilizes techniques such as fMRI, eye-tracking and experience sampling to enhance our understanding of the neurobiological mechanisms predicting cognitive and mental health outcomes following psychedelic use, initially investigating the effects of DMT.
View stakeholder →